MX9401406A - Agentes receptores de adenosina selectivos para intensificar el conocimiento. - Google Patents
Agentes receptores de adenosina selectivos para intensificar el conocimiento.Info
- Publication number
- MX9401406A MX9401406A MX9401406A MX9401406A MX9401406A MX 9401406 A MX9401406 A MX 9401406A MX 9401406 A MX9401406 A MX 9401406A MX 9401406 A MX9401406 A MX 9401406A MX 9401406 A MX9401406 A MX 9401406A
- Authority
- MX
- Mexico
- Prior art keywords
- intensify
- knowledge
- pct
- selective adenosine
- receiving agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un grupo de compuestos que son derivados de xantina y que actúan en forma selectiva en los receptores A1 de adenosina. Los antagonistas de adenosina que actúan en el receptor A1 despolarizan las neuronas potsinápticas e incrementan la liberación de un numero de neurotransmisores desde la presinápsis, incluyendo la acetilcolina, glutamato, serotorina, y norepinefrina. Esta es una acción potencial para el tratamiento de pérdida del conocimiento como aquéllas asociadas con la enfermedad de Alzheimer, así como los transmisores que se han encontrado implicados en el aprendizaje y la memoria, y cada uno de estos transmisores se debilita en la enfermedad de Alzheimer. Algunos de los compuestos antagonistas de la A1 descritos en la presente invención incrementan la actividad de las neuronas en el hipocampo en un modelo de aprendizaje in vitro de potenciación durante períodos largos, y antagonizan una pérdida inducida por escopolamina en un modelo de aprendizaje in vivo en el laberinto con agua. Por lo tanto, estos compuestos tiene posibilidad para los efectos de intensificación del conocimiento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2350193A | 1993-02-26 | 1993-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9401406A true MX9401406A (es) | 1994-08-31 |
Family
ID=21815459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9401406A MX9401406A (es) | 1993-02-26 | 1994-02-24 | Agentes receptores de adenosina selectivos para intensificar el conocimiento. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5840729A (es) |
| EP (1) | EP0686155B1 (es) |
| JP (1) | JPH08512281A (es) |
| KR (1) | KR100315898B1 (es) |
| CN (1) | CN1041418C (es) |
| AT (1) | ATE169019T1 (es) |
| AU (1) | AU680241B2 (es) |
| CA (1) | CA2155130C (es) |
| DE (1) | DE69412073T2 (es) |
| DK (1) | DK0686155T3 (es) |
| ES (1) | ES2120025T3 (es) |
| HU (1) | HUT72677A (es) |
| IL (1) | IL108750A (es) |
| MX (1) | MX9401406A (es) |
| NO (1) | NO311920B1 (es) |
| NZ (1) | NZ262984A (es) |
| TW (1) | TW261532B (es) |
| WO (1) | WO1994019349A1 (es) |
| ZA (1) | ZA941176B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303624B1 (en) * | 1997-03-18 | 2001-10-16 | Fujisawa Pharmaceutical Co., Ltd. | Preventives and remedies for hyperphosphatemia |
| CN100528874C (zh) | 1998-06-02 | 2009-08-19 | Osi药物公司 | 吡咯并[2,3d]嘧啶组合物及其应用 |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
| US7504407B2 (en) | 2001-11-30 | 2009-03-17 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 and A3 receptors and uses thereof |
| CN1620294A (zh) | 2001-12-20 | 2005-05-25 | Osi药物公司 | 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途 |
| JP2005538950A (ja) * | 2002-05-15 | 2005-12-22 | ジェンザイム、コーポレーション | ２−アルキルシステイン、２−（ヒドロキシル化フェニル）−４−アルキルチアゾリン−４−カルボン酸およびそれらの誘導体の合成 |
| WO2004086047A2 (en) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1) |
| US20070078148A1 (en) * | 2003-12-09 | 2007-04-05 | Kyowa Hakko Kogyo Co., Ltd. | Agents for preventing and/or treating higher brain dysfunctions |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE8817122U1 (de) * | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 55218 Ingelheim | Neue Xanthinderivate mit Adenosinantogenistischer Wirkung |
| US5047534A (en) * | 1990-03-26 | 1991-09-10 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine receptor agents |
| JPH0455150A (ja) * | 1990-06-22 | 1992-02-21 | Takata Kk | 助手席用エアバッグ装置 |
| DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| US5087827A (en) * | 1991-02-11 | 1992-02-11 | Tektronix, Inc. | Variable voltage transition circuit |
| US5208240A (en) * | 1991-03-12 | 1993-05-04 | Merrell Dow Pharmaceuticals Inc. | 8-substituted purines as selective adenosine receptor agents |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
-
1994
- 1994-01-27 CA CA002155130A patent/CA2155130C/en not_active Expired - Fee Related
- 1994-01-27 NZ NZ262984A patent/NZ262984A/en unknown
- 1994-01-27 HU HU9502495A patent/HUT72677A/hu unknown
- 1994-01-27 KR KR1019950703577A patent/KR100315898B1/ko not_active IP Right Cessation
- 1994-01-27 US US08/500,991 patent/US5840729A/en not_active Expired - Fee Related
- 1994-01-27 ES ES94910661T patent/ES2120025T3/es not_active Expired - Lifetime
- 1994-01-27 CN CN94191309A patent/CN1041418C/zh not_active Expired - Fee Related
- 1994-01-27 DE DE69412073T patent/DE69412073T2/de not_active Expired - Fee Related
- 1994-01-27 AT AT94910661T patent/ATE169019T1/de not_active IP Right Cessation
- 1994-01-27 DK DK94910661T patent/DK0686155T3/da active
- 1994-01-27 JP JP6518986A patent/JPH08512281A/ja active Pending
- 1994-01-27 AU AU62968/94A patent/AU680241B2/en not_active Ceased
- 1994-01-27 WO PCT/US1994/001009 patent/WO1994019349A1/en active IP Right Grant
- 1994-01-27 EP EP94910661A patent/EP0686155B1/en not_active Expired - Lifetime
- 1994-02-21 ZA ZA941176A patent/ZA941176B/xx unknown
- 1994-02-22 TW TW083101485A patent/TW261532B/zh active
- 1994-02-23 IL IL10875094A patent/IL108750A/xx not_active IP Right Cessation
- 1994-02-24 MX MX9401406A patent/MX9401406A/es not_active IP Right Cessation
-
1995
- 1995-08-25 NO NO19953353A patent/NO311920B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1994019349A1 (en) | 1994-09-01 |
| US5840729A (en) | 1998-11-24 |
| EP0686155B1 (en) | 1998-07-29 |
| HU9502495D0 (en) | 1995-10-30 |
| DE69412073D1 (de) | 1998-09-03 |
| IL108750A (en) | 2000-09-28 |
| DK0686155T3 (da) | 1999-02-01 |
| KR100315898B1 (ko) | 2002-02-28 |
| NZ262984A (en) | 1997-05-26 |
| HUT72677A (en) | 1996-05-28 |
| NO953353D0 (no) | 1995-08-25 |
| ZA941176B (en) | 1994-09-20 |
| NO311920B1 (no) | 2002-02-18 |
| CN1041418C (zh) | 1998-12-30 |
| CA2155130C (en) | 1994-09-01 |
| TW261532B (es) | 1995-11-01 |
| DE69412073T2 (de) | 1999-02-18 |
| ATE169019T1 (de) | 1998-08-15 |
| AU680241B2 (en) | 1997-07-24 |
| CN1118599A (zh) | 1996-03-13 |
| AU6296894A (en) | 1994-09-14 |
| IL108750A0 (en) | 1994-05-30 |
| NO953353L (no) | 1995-08-25 |
| CA2155130A1 (en) | 1994-09-01 |
| ES2120025T3 (es) | 1998-10-16 |
| JPH08512281A (ja) | 1996-12-24 |
| EP0686155A1 (en) | 1995-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960701051A (ko) | 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases) | |
| DE69622031D1 (de) | INDOLDERIVATE ALS cGMP-PDE INHIBITOREN | |
| ATE185548T1 (de) | Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress | |
| TR199800077T1 (xx) | Kontroll� ��z�len paroksetin terkipleri. | |
| ES2091689T3 (es) | Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos. | |
| BR9203277A (pt) | Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao | |
| MX9401406A (es) | Agentes receptores de adenosina selectivos para intensificar el conocimiento. | |
| FI944014A0 (fi) | Makrolidien desosaminojohdannaiset immuunivastetta heikentävinä aineina ja sieniä vastustavina aineina | |
| IT1244886B (it) | Dicarbonati e uretani dell'acido 4,5-diidrossi- e 4,5,8-triidrossi- 9,10-diidro-9,10-diosso-2-antracencarbossilico ad azione terapeutica | |
| ATE215525T1 (de) | Stabile derivate von ubiquinol, verfahren zu ihrer herstellung und ihre pharmazeutische anwendung | |
| SE9302218D0 (sv) | New use | |
| MX9201288A (es) | Metodo de tratamiento. | |
| ZA965749B (en) | Use of allylamines. | |
| DE69310721D1 (de) | Zuckerderivate von makroliden | |
| PT958290E (pt) | Derivados de 1,4-di-hidropiridina e seu uso em terapia | |
| DK0674508T3 (da) | 4-guanidinobutyramid til forbedring af blodcirkulation | |
| IL107917A0 (en) | Triazoloquinazolines, their preparation and their use as medicaments | |
| DE69407180D1 (de) | Fluoro-nukleosid-reinigung | |
| NO974687L (no) | Kondenserte <beta>-carboliner |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| MM | Annulment or lapse due to non-payment of fees |